Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Hutchmed endometrial cancer treatment gets priority review in China
(Sharecast News) - Hutchmed China announced the acceptance and granting of priority review by the China National Medical Products Administration (NMPA) for a new drug application combining fruquintinib and sintilimab for the treatment of advanced endometrial cancer on Tuesday. The AIM-traded firm said the indication, applied for in conjunction with Innovent Biologics, targets tumours that had failed prior systemic therapy but were not eligible for curative surgery or radiation.
It said the application was supported by data from the FRUSICA-1 study, a phase two investigation of the combination in patients with recurrent, progressing, or intolerant endometrial cancer following platinum-based doublet chemotherapy.
The board said the primary endpoint of FRUSICA-1 was the objective response rate (ORR), assessed by an independent review committee (IRC), with secondary endpoints including disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), and pharmacokinetic (PK) assessments.
Data from the study would be presented at an upcoming medical conference, and had been registered on clinicaltrials.gov.
The NMPA granted breakthrough therapy designation to the fruquintinib and sintilimab combination in July last year, acknowledging its potential to address a serious condition with limited treatment options, backed by substantial clinical evidence of advantages over existing therapies.
"This is the first regulatory filing for the combination of fruquintinib and the immune checkpoint inhibitor sintilimab," said Dr Michael Shi, head of research and development and chief medical officer at Hutchmed.
"It also represents an important step closer to reshaping the treatment landscape for this challenging disease in China.
"Endometrial cancer remains one of the most common gynaecological malignancies; we look forward to bringing this much-awaited treatment advancement to endometrial cancer patients to improve their treatment outcome."
At 1144 GMT, shares in Hutchmed China were down 0.56% at 266p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
